Aspen Neuroscience IPO Bets on Parkinson's Brain Cells Made From Skin

Aspen Neuroscience, the biotech that makes replacement brain cells from a patient's own skin, has gone public. The company priced its initial public offering at $15 per share to raise about $140.6 million, and its stock was set to begin trading on the Nasdaq Global Select Market on Friday under the ticker ASPE. With those funds it intends to push sasineprocel, a one time, made to order cell therapy for Parkinson's disease, toward a pivotal trial. For Silicon Valley investors used to seeing biotech listings stall and then start up again, the deal is a test of whether public markets are willing to put money behind medicine built one patient at a time.

What Aspen is building

Parkinson's disease slowly erodes the neurons in the brain that produce dopamine, the chemical messenger that helps control movement. Levodopa and other drugs on the market today supply dopamine from outside, but they become less consistent over time and do not put back the cells that have been lost.

Aspen Neuroscience is set on doing just that. Starting with a small skin sample from the patient, the company reprograms the cells into induced pluripotent stem cells and then into precursors of dopamine neurons. Surgeons implant them in the putamen, the part of the brain where Parkinson's causes a loss of dopamine signaling. Since the cells are the patient's own, Aspen is counting on the immune system to accept them with no need for long term immunosuppressive drugs.

The San Diego company has named the product sasineprocel, formerly known as ANPD001, and it is meant to be a single course of treatment rather than a pill taken every day.

The IPO by the numbers

Aspen put 9,375,000 shares on the market at $15, the floor of its projected $15 to $17 range, for about $140.6 million in gross proceeds before underwriting fees. The underwriters have 30 days to buy as many as 1,406,250 additional shares, and the offering is expected to close by November 2. The joint bookrunners are Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank and Oppenheimer & Co.

The low end pricing speaks for itself. Investors will put money behind a clinical stage cell therapy company like Aspen, but not at any price. Aspen was not the only one in line: Boston's Bambusa Therapeutics also priced at the bottom of its range this week even as it put more shares up for sale, and Corxel Pharma, an obesity drug developer, announced plans to go public through a merger with a special purpose acquisition company.

What the data says so far

Sasineprocel is being tested in ASPIRO, a Phase 1/2a clinical trial in people with mid stage to moderately advanced Parkinson's disease. Fifteen patients had been treated as of the summer.

Back in March, at the AD/PD International Conference in Copenhagen, the company presented 12 month figures for the first eight of those patients, half on a higher dose and half on a lower one. There were no serious surgical complications, no symptomatic bleeding or strokes and no severe graft induced dyskinesia. PET scans monitoring dopamine output pointed to cell survival and engraftment. On average, patients gained about two extra hours a day of "good on" time, when symptoms are in check, and several were able to cut back on levodopa.

Encouraging though the numbers are, there are limits. In an open label study of this size, doctors and patients know who received the therapy, so it is difficult to separate a genuine biological response from expectation. Nor can the trial yet show how long the benefit lasts or whether a higher dose works better.

The FDA has given sasineprocel Fast Track and Regenerative Medicine Advanced Therapy status, which can lead to more regular contact with regulators and a faster review if the data warrants it. Aspen is looking to start a Phase 3 trial in the second half of 2027.

Manufacturing is the real product

The factory is as important as the biology when it comes to a personalized therapy. Each dose is made from the cells of an individual patient, and reports say it takes roughly four months to produce. A conventional drug is quite different: a single batch can serve thousands of people.

Aspen has set about addressing the issue. In June, the company finished dosing its third and fourth cohorts of patients with a cryopreserved form of the therapy that can be thawed and injected, a version intended to be stored and shipped more like a commercial product.

The company described the new formulation as a step toward scalable manufacturing and commercial readiness ahead of Phase 3. It is a challenge Silicon Valley is no stranger to: turning patient specific cell production into a business rather than a one off comes down to process control, quality data and automation.

Why this matters beyond Parkinson's

Aspen is one data point in a wider move toward medicines made for the individual. Sparknify's coverage of a personalized cancer vaccine earlier this month looked at the same idea from a different vantage point, with a treatment keyed to a single patient's tumor. Patient derived cell therapy takes that reasoning further and rebuilds tissue from the patient's own cells.

If Aspen succeeds, its model could be applied to other diseases where particular cell types have been lost, from eye disorders to diabetes. A failure could lead investors to write off personalized cell therapy as too expensive and too slow to build a company around.

What will a public Aspen mean for personalized cell therapy?

The near term outlook is a well financed Phase 3. The IPO gives Aspen capital to scale up manufacturing and run a controlled trial large enough to answer the questions the open label study leaves open. A good pivotal result would put sasineprocel among the first patient derived replacement cell therapies with a clear shot at approval for a common neurological disease. It would also give the rest of the field a template for dealing with regulators and investors.

But there are real concerns. Brain surgery is risky, and a bigger trial could turn up side effects not seen in a few dozen patients. At roughly four months per patient, the manufacturing cycle is costly, and doing it for many patients will require automation that has not been tested at commercial scale. Then there is price and access. Insurers will want long term proof before paying for a one time therapy to replace neurons, which is bound to cost far more up front than a lifetime of generic pills.

There is also debate over the right approach. Several groups, including large pharmaceutical companies, are developing off the shelf therapies from donor stem cells, which can be made in large batches but may require immune suppression. Supporters of the autologous method say using a patient's own cells avoids rejection and the side effects of immunosuppressants. Critics make an economic case that producing one batch for every patient will always be harder. More data from both camps should arrive over the next two years, and that will shape where the money goes.

How the market responds is still an open question. Pricing at the bottom of the range shows investors are interested but wary, and the way ASPE trades in the months ahead will show whether other clinical stage cell therapy companies can follow it onto the Nasdaq.

Things to watch include the design and start date of the Phase 3, longer follow up on the first ASPIRO patients, data on the cryopreserved formulation, how long manufacturing takes per patient, and how the stock behaves after the lockup period ends. For founders building quality control and automation tools for biomanufacturing, Aspen is a demand signal: personalized medicine will need factories of its own.

In short, Aspen is asking public investors to bet that the next major Parkinson's treatment will be made from patients themselves.

Subscribe to Sparknify for Silicon Valley tech news and the people behind it.